Hedelix (Extract Of Hedera Helix Folium (2.2 – 2.9 : 1), Extracting Agent: Ethanol 50% (V / V), Propylene Gly)

Hedelix is indicated for the symptomatic relief of common respiratory conditions where mucus accumulation contributes to coughing.

• Temporary relief of dry or productive cough associated with upper respiratory tract infections.
• Adjunctive support in mild bronchitis to promote expectoration.
• Management of cough related to the common cold.
• Use as a non‑prescription option for individuals seeking a plant‑based expectorant.
• Helpful in soothing throat irritation caused by persistent coughing.
• May be used alongside hydration measures to facilitate mucus clearance.

Side‑effect profile of Hedelix reflects the typical reactions observed with ivy‑leaf extracts.

Common

• Mild gastrointestinal discomfort such as nausea or stomach upset.
• Transient taste disturbance or a bitter after‑taste.
• Slight increase in salivation.
• Rare skin redness at the oral mucosa.
• Dizziness or light‑headedness, especially after high doses.

Serious

• Allergic reactions ranging from urticaria to angio‑edema.
• Hepatic enzyme elevation in susceptible individuals.
• Severe bronchospasm (very uncommon).
• Persistent vomiting.
• Significant hypotension.

When considering Hedelix, several precautionary measures should be observed to ensure safe use.

• Not recommended for children under 6 years of age without medical supervision.
• Avoid use in individuals with known hypersensitivity to ivy or related plants (Araliaceae family).
• Caution in patients with hepatic impairment; monitor liver function if used long term.
• Pregnant or breastfeeding women should consult a healthcare professional before use.
• Do not exceed the recommended daily amount indicated on the product label.
• Concomitant use with other expectorants may increase the risk of gastrointestinal irritation.

Hedelix may interact with certain medications; awareness of these interactions helps prevent adverse outcomes.

Avoid

• Concurrent use with potent CYP450 inhibitors that could raise systemic exposure to ivy constituents (e.g., ketoconazole).
• Combining with other mucolytic or expectorant agents may cause excessive bronchial secretions.
• Use together with antihistamines that cause dry mouth may reduce the expectorant effect.

Use with caution

• Co‑administration with bronchodilators (e.g., salbutamol) – monitor for additive smooth‑muscle relaxation.
• Patients taking anticoagulants (warfarin, DOACs) – observe for any change in bleeding tendency.
• Individuals on hepatotoxic drugs – consider liver function monitoring.